The purpose of the study. To evaluate the results of using a drug based on benzidamine hydrochloride in the treatment regimens of acute respiratory viral infections in children today. Materials and methods. The study included 875 children aged 3 to 18 years with acute respiratory viral infections, which occurred in mild or moderate forms, and were treated on an outpatient basis. During the non-interventional study, a retrospective analysis of information from medical records was made. The main group included 318 children who were recommended therapy with a drug based on benzidamine hydrochloride, the comparison group included 557 children who received other topical drugs. Results. Recovery was statistically significantly earlier in the group receiving benzidamine hydrochloride: from the moment of initiation of therapy, the disease period in the main group was 6.78±1.72 days, while in the comparison group it was 1.34 days longer – 8.12±3.32. It was found that benzidamine hydrochloride significantly reduces the period of tickling and sore throat from 5.10±1.38 in the comparison group to 4.08±1.41 in the main group, hyperemia of the posterior pharyngeal wall – from 8.11±3.27 in the comparison group to 6.68±1.6 days in the main group, hyperemia of the tonsils – from 7.85±1.84 in the comparison group to 6.86±1.77 in the main group. Relief of dry cough was recorded in the group receiving benzidamine hydrochloride at 4.23±1.66 days, and in the group where other drugs were used – at 4.64±1.85 days. According to other indicators, no significant differences were found between the compared groups. Conclusion. The administration of a drug based on benzidamine hydrochloride as part of complex therapy statistically significantly, on average, reduces the total duration of acute respiratory viral infections in children from 3 years old by 1.34 days, reduces the period of tickling and sore throat by 1.08 days; by 1.43 days – visual manifestations of pharyngitis, by 1.0 days – tonsillitis; reduces the duration of dry cough.